AcouSort receives 1.25 million SEK in Vinnova funding for the development of individualized stem cell treatments

AcouSort AB (publ) (“AcouSort”) receives funding from Vinnova for the project IndiCell. The aim of the project is to enable the transfer of novel stem cell treatments from research to a clinical setting. The project is planned to run over five years and generate revenues of 1.25 million SEK to AcouSort.

– We are very excited to start this project where we will contribute with our unique acoustic technology to implement clinical work flows for individualized stem cell therapy. Together with the Blue4Therapy project, we now have two publicly funded projects relating to stem cell therapies. This means we can further accelerate our application development aiming for stem cell related clinical treatments, an area with very large commercial potential, says AcouSort’s CEO Torsten Freltoft. 

In the future, cell replacement therapies for incurable diseases will be derived from induced pluripotent stem cells from the patient’s own healthy cells. The overall aim of IndiCell is to build up a unique and strong environment focusing on induced pluripotent stem cell derived therapies to lower the risks and overcome hurdles for the translation from basic science to innovations and further to clinical applications. In the project, an innovation milieu will be built up, consisting of operators from three different sectors, academic scientists (Lund University, Karolinska Institutet and KTH Royal Institute of Technology), health care (Vecura, SUS) and SMEs (BioLamina, AcouSort, MagicBioprocessing). AcouSort’s role will be to develop standard operating procedures for cell handling based on acoustic separation. IndiCell is one of 11 precision health innovation environments that Vinnova is investing in, with the purpose of paving the way for a more preventive, accurate and equal heath care and strengthening Sweden as a life science nation.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-post: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.